Wall Street Journal
New supplies of two currently hard-to-find cancer drugs are on the way, according to the FDA.
As Dow Jones Newswires reports, the FDA said it would allow the temporary importation of Lipodox, made by Sun Pharma Global FZE and distributed by Caraco Pharmaceutical Laboratories, as a substitute for Johnson & Johnson’s Doxil. The drugs have the same active ingredient.
Doxil has been in short supply since about mid-2011. New supplies of Lipodox are “expected to end the shortage and fully meet patient needs in the coming weeks,” the FDA says.
The FDA also said
it had approved a new manufacturer — APP Pharmaceuticals — of
preservative-free methotrexate, a drug that is used to treat a type of
children’s leukemia and has also been in short supply. The drug should be available in March, the agency says... Read More